Zevra net income drops 88.29% to $8.8 million in Q2 FY26; revenue rises 53% to $39.7 million - ZVRA News | RalliesZevra net income drops 88.29% to $8.8 million in Q2 FY26; revenue rises 53% to $39.7 million
Z
ZVRA• Zevra reports higher revenue and lower net income in Q2 FY26
- Zevra Therapeutics posted Q2 2026 revenue of $39.7 million, up 53% from Q2 2025.
- Net income fell to $8.8 million; diluted EPS declined to $0.14.
- MIPLYFFA net revenue was $30.2 million; global Expanded Access Program reimbursements were $9 million.
- Cash, cash equivalents and investments totaled $260.2 million at June 30, 2026.
- CEO Neil F. McFarlane cited strong U.S. commercial execution; Zevra requested EU re-examination of its arimoclomol marketing application.
FSCO
•
